How to Withdraw a Drug: FDA’s Final Decision on Avastin

The “streamlined withdrawal” process for Avastin in metastatic breast cancer gave Genentech an extra 11 months to prepare for the transition to off-label status. It also gave FDA time to make preparations of its own.

More from Post-Marketing Regulation & Studies

More from Product Reviews